G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 14.89 USD -3% Market Closed
Market Cap: 923.6m USD

GH Research PLC
Other Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

GH Research PLC
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Other Equity
-$12.6m
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Other Equity
$69.6m
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
1%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Other Equity
-$569.9m
CAGR 3-Years
29%
CAGR 5-Years
-25%
CAGR 10-Years
-9%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Other Equity
-$23.7m
CAGR 3-Years
5%
CAGR 5-Years
-2%
CAGR 10-Years
0%
Cosmo Pharmaceuticals NV
SIX:COPN
Other Equity
€637k
CAGR 3-Years
-57%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
Ovoca Bio PLC
LSE:OVB
Other Equity
€5.5m
CAGR 3-Years
13%
CAGR 5-Years
3%
CAGR 10-Years
2%
No Stocks Found

GH Research PLC
Glance View

Market Cap
923.6m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
2.94 USD
Overvaluation 80%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's Other Equity?
Other Equity
-12.6m USD

Based on the financial report for Dec 31, 2024, GH Research PLC's Other Equity amounts to -12.6m USD.

What is GH Research PLC's Other Equity growth rate?
Other Equity CAGR 3Y
-29%

Over the last year, the Other Equity growth was -20%. The average annual Other Equity growth rates for GH Research PLC have been -29% over the past three years .

Back to Top